Skip to contentpdufa.bio

Talzenna (talazoparib)

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

The FDA approved Talzenna (talazoparib) on Oct 26, 2026. It is a Pfizer Inc. program in metastatic androgen pathway modulation-naive or -sensitive prostate cancer with HRR gene mutations (with enzalutamide). 1 FDA decision on record below.

PFE catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

FDA approval tracked on pdufa.bio: metastatic androgen pathway modulation-naive or -sensitive prostate cancer with HRR gene mutations (with enzalutamide) (approved Oct 26, 2026). Earlier approvals may not be listed here; the FDA label is the full record. Sponsor: Pfizer Inc. (PFE). Approval record: Supplemental NDA under Priority Review, reviewed under Project Orbis. Per the FDA, TALAPRO-3 (NCT04821622) randomized 599 patients with HRR gene-mutated disease 1:1 to talazoparib or placebo, each with enzalutamide and continuous androgen deprivation; radiographic progression-free survival hazard ratio 0.48 (95% CI 0.36 to 0.65), p<0.0001, median not reached versus 45.8 months. Talazoparib 0.5 mg orally once daily with enzalutamide. Market-cap tier at the time we tracked it: Large. We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Oct 26, 2026 ✓ ApprovedPFE

Questions

When is Talzenna (talazoparib)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for Talzenna (talazoparib); 1 FDA decision is on record below.

What happened at Talzenna (talazoparib)'s most recent FDA decision?

On Oct 26, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

What is Talzenna (talazoparib) used for?

In our records Talzenna (talazoparib) is FDA-approved for metastatic androgen pathway modulation-naive or -sensitive prostate cancer with HRR gene mutations (with enzalutamide) (approved Oct 26, 2026). Other approved uses may not be tracked here; the FDA label is the full record.

Who makes Talzenna (talazoparib)?

Pfizer Inc. (PFE).

Has Talzenna (talazoparib) been approved by the FDA?

Yes. The FDA approved an application for Talzenna (talazoparib) on Oct 26, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.